title: Continuous administration of a P450 aromatase inhibitor induces polycystic ovary syndrome with a metabolic and endocrine phenotype in female rats at adult age.
abstract: Studying the mechanisms for the complex pathogenesis of polycystic ovary syndrome (PCOS) requires animal models with endocrine, reproductive, and metabolic features of the syndrome. Hyperandrogenism seems to be a central factor in PCOS, leading to anovulation and insulin resistance. In female rats, continuous administration of letrozole, a nonsteroidal inhibitor of P450 aromatase, at 400 μg/d starting before puberty induces hyperandrogenemia and reproductive abnormalities similar to those in women with PCOS. However, despite high circulating testosterone levels, these rats do not develop metabolic abnormalities, perhaps because of their supraphysiological testosterone concentrations or because estrogen synthesis is completely blocked in insulin-sensitive tissues. To test the hypothesis that continuous administration of lower doses of letrozole starting before puberty would result in both metabolic and reproductive phenotypes of PCOS, we performed a 12-wk dose-response study. At 21 d of age, 46 female Wistar rats were divided into two letrozole groups (100 or 200 μg/d) and a control group (placebo). Both letrozole doses resulted in increased body weight, inguinal fat accumulation, anovulation, larger ovaries with follicular atresia and multiples cysts, endogenous hyperandrogemia, and lower estrogen levels. Moreover, rats that received 200 μg/d had insulin resistance and enlarged adipocytes in inguinal and mesenteric fat depots, increased circulating levels of LH, decreased levels of FSH, and increased ovarian expression of Cyp17a1 mRNA. Thus, continuous administration of letrozole, 200 μg/d, to female rats for 90 d starting before puberty results in a PCOS model with reproductive and metabolic features of the syndrome.
authors.affiliation: Institute of Neuroscience and Physiology, Department of Physiology, Sahlgrenska Academy, Göteborg University, Box 434, SE-405 30 Göteborg, Sweden.
authors.forename: Manuel
authors.initials: M
authors.lastname: Maliqueo
authors.forename: Miao
authors.initials: M
authors.lastname: Sun
authors.forename: Julia
authors.initials: J
authors.lastname: Johansson
authors.forename: Anna
authors.initials: A
authors.lastname: Benrick
authors.forename: Fernand
authors.initials: F
authors.lastname: Labrie
authors.forename: Henrik
authors.initials: H
authors.lastname: Svensson
authors.forename: Malin
authors.initials: M
authors.lastname: Lönn
authors.forename: Antoni J
authors.initials: AJ
authors.lastname: Duleba
authors.forename: Elisabet
authors.initials: E
authors.lastname: Stener-Victorin
mesh_terms: D000818:Animals; D047072:Aromatase Inhibitors / Q000494:pharmacology*; D005260:Female; D000077289:Letrozole; D009570:Nitriles / Q000494:pharmacology*; D011085:Polycystic Ovary Syndrome / Q000139:chemically induced* / Q000473:pathology; D051381:Rats; D017208:Rats, Wistar; D014230:Triazoles / Q000494:pharmacology*
chemical_list: D047072:Aromatase Inhibitors; D009570:Nitriles; D014230:Triazoles; D000077289:Letrozole